The Alzheimer's treatment landscape is expanding dramatically, with nearly 200 clinical trials now underway testing more than 150 novel drugs. Two FDA-approved medications, Leqembi and Kisunla, are already slowing cognitive decline in early-stage patients by directly targeting amyloid plaques in the brain. But the real excitement lies ahead: pill-based therapies, non-invasive brain stimulation, and next-generation drugs targeting multiple pathways beyond amyloid are all moving through clinical trials. What Are Disease-Modifying Treatments, and Why Do They Matter? For decades, Alzheimer's medications only masked symptoms like memory loss and confusion. Leqembi (lecanemab) and Kisunla (donanemab), approved in 2023 and 2024 respectively, represent a fundamental shift. These drugs don't just treat symptoms; they interrupt the disease process itself by clearing toxic amyloid-beta buildup from the brain. Both have been shown to slow cognitive decline in people with early-stage Alzheimer's, offering the potential to halt disease progression rather than simply slow its symptoms. The challenge now is refining how these drugs are delivered and dosed. Both medications can cause side effects called amyloid-related imaging abnormalities (ARIA), which include microbleeds or brain swelling. Researchers are working with the FDA to reduce these risks while maintaining effectiveness. A major breakthrough came recently when the FDA approved an at-home injectable form of Leqembi, allowing patients to self-administer the drug instead of traveling to clinics for intravenous infusions. The FDA is expected to decide in May 2026 whether to also approve initial starter doses for home use. What New Alzheimer's Drugs Are in Development? The pipeline of experimental treatments reflects a broader, more diverse approach to tackling Alzheimer's. Researchers are developing drugs that target different aspects of the disease, not just amyloid plaques. Here's what's coming: - Trontinemab: This next-generation amyloid-clearing drug recently entered Phase III clinical trials. It uses Roche's proprietary Brainshuttle technology to cross the blood-brain barrier more effectively. In earlier trials, 92% of people receiving trontinemab had no measurable plaques after 28 weeks of treatment, with low rates of ARIA side effects. Results from the two Phase III trials, TRONTIER 1 and 2, are expected in 2028. - Blarcamesine: Currently in Phase II/III trials, this pill-based medication takes a different approach. Instead of directly clearing amyloid, it activates the sigma-1 receptor, which helps cells remove toxic proteins more efficiently. Early safety data and signs of effectiveness have been encouraging. - ALZ-801: This oral medication targets the formation of tau tangles, another hallmark of Alzheimer's. A recently completed Phase 3 trial called APOLLOE4 tested it in people with two copies of the APOE4 risk gene. About 10% of participants showed improved cognition, with younger patients and those earlier in their diagnosis showing the strongest benefits. Are Non-Drug Treatments Being Tested for Alzheimer's? Beyond medications, researchers are exploring non-invasive therapies that could transform Alzheimer's care. In late 2024, a Phase 2 clinical trial by Sinaptica Therapeutics showed that personalized, non-invasive brain stimulation slowed cognitive decline by 44% while improving behavioral symptoms and maintaining daily function in people with mild-to-moderate Alzheimer's. The company is continuing to test this approach in additional trials. Another promising technology involves flickering lights and sound. Preliminary results from a trial sponsored by Cognito Therapeutics suggested that flickering lights and sound at around 40 Hz could slow cognitive decline and brain volume loss. A Phase 3 trial of this technology is currently underway. Focused ultrasound represents another frontier. This technology uses very high frequency sound waves to temporarily open the blood-brain barrier, giving treatments unprecedented access to the brain. This makes it easier for anti-amyloid antibodies to reach their targets and allows biomarkers in the brain to enter the bloodstream for testing. How to Stay Informed About Alzheimer's Treatment Options - Talk to Your Doctor: If you or a loved one has been diagnosed with early-stage Alzheimer's, discuss whether Leqembi or Kisunla might be appropriate. Your doctor can explain the benefits and potential side effects specific to your situation. - Ask About Clinical Trials: Nearly 200 trials are currently recruiting participants. Ask your healthcare provider whether you might qualify for any experimental treatments that align with your disease stage and health profile. - Explore Lifestyle Factors: While medications and clinical trials offer hope, research continues to show that certain lifestyle habits can help reduce your risk of developing Alzheimer's in the first place. Discuss preventive strategies with your doctor. The Alzheimer's treatment landscape has transformed dramatically in just two years. Where patients once had only symptom-management options, they now have access to disease-modifying drugs and can potentially enroll in trials testing cutting-edge approaches. The diversity of treatments in development, targeting everything from amyloid plaques to tau tangles to cellular garbage removal systems, suggests that future Alzheimer's care will be more personalized and effective than ever before.
